Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Case Report



INVASIVE PULMONARY ASPERGILLOSIS FOLLOWING BEVACIZUMAB TREATMENT FOR NON-SMALL CELL LUNG CANCER

Khadija Bellahammou, Asmaa Lakhdissi, Akkar Othman,Salmi Narimane, Ibrahim El Ghissassi, Fadoua Rais, Naoual Benhmidou, Hind M'rabti, Hassan Errihani.

Abstract
Bevacizumab is a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor; it is actually approved for the treatment of unresectable, locally advanced and metastatic non-small cell lung cancer in association with chemotherapy and as maintenance therapy. Infection risk due to use of bevacizumab is a very rare event. Several cases of aspergillosis in patients treated with monoclonal antibodies have been reported, mostly following treatment with tumor necrosis factor alpha blockers. We present a case of a 60 year-old patient treated for stage IV non-small cell lung cancer, who has been diagnosed with invasive aspergillosis following bevacizumab treatment, and, we postulate that bevacizumab may contribute to this infection.

Key words: Invasive aspergillosis, Bevacizumab


Full-text options

Full-text Article




Advertisement
American Journal of Diagnostic Imaging

SUBMIT YOUR ARTICLE NOW




ScopeMed.com
BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.